康复新液联合雷贝拉唑治疗咽喉反流 40例疗效分析

目的分析康复新液联合雷贝拉唑在治疗咽喉反流方面的临床疗效。方法选取 82例于 2020年 8月至 2021年 3月期间在蚌埠医学院第一附属医院门诊就诊的咽喉反流病人。采用抛硬币法随机分为两组，各 41例。其中给予雷贝拉唑肠溶胶囊联合使用康复新液的为观察组；仅给予雷贝拉唑肠溶胶囊的为对照组。两组均连续用药 8周，在用药 4周及 8周时分别比较两组的总有效率。结果观察组剔除 1例，最终纳入 40例。对照组无剔除病例。两组治疗前的年龄、性别、病程、反流症状指数( RSI)量表评分及反流体征评分( RFS)量表评分差异无统计学意义( P>0.05)。连续用药 4周后，观察组的总有效率为

Therapeutic effect of Kangfuxin combined with rabeprazole in the treatment of 40 cases of laryngopharyngeal reflux

Objective To analysis the clinical efficacy of Kangfuxin combined with rabeprazole in the treatment of laryngopharyngeal reflux (LPR).Methods A total of 82 patients with LPR were selected from the Department of Otolaryngology, the First AffiliatedHospital of Bengbu Medical College from August 2020 to March 2021. The patients were randomly divided into two groups with 41 cases in each group. The observation group was given rabeprazole capsules combined with Kangfuxin, while the control group was given rabeprazole capsules only. The total effective rate of the two groups were compared at 4 and 8 weeks.Results In the observation group,1 case was excluded and 40 cases were finally included. No cases were excluded in the control group.There was no significant difference in age, gender, course of disease, RSI and RFS between the two groups before treatment (P > 0.05). After 4 weeks of continuousmedication, the total effective rate of the observation group was 65.0%, and that of the control group was 39.0%. After 8 weeks of continuous medication, the total effective rate of the observation group was 87.5%, and that of the control group was 63.4%. The two efficacyevaluations of the observation group were higher than those of the control group, and the difference between the two groups was statistically significant (P<0.05).Conclusion Kangfuxin combined with rabeprazole has good clinical effect in the treatment of LPR, which can be popularized in clinical application.